Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative price increase of over 20% compared to the market benchmark within the next six months [17]. Core Views - The company reported a revenue of 1.51 billion yuan for Q1 2025, reflecting a year-on-year growth of 11.3%, and a net profit of 300 million yuan, which is a 13.4% increase year-on-year [2]. - The increase in various expense ratios in Q1 2025, including sales expense ratio at 33.6% (up 1.5 percentage points), management expense ratio at 4.9% (up 1.4 percentage points), and R&D expense ratio at 12.7% (up 2.2 percentage points), is attributed to stock incentive costs and increased R&D investments [3]. - The company continues to increase its R&D investment, with a total of 721 million yuan in 2024, a 17.48% increase year-on-year, and a workforce of 911 R&D personnel, up 6.7% year-on-year. The company has 14 innovative drug projects in progress, with significant advancements expected in 2024 [4]. Financial Forecast and Investment Recommendations - The company is projected to achieve revenues of 6.59 billion yuan, 7.69 billion yuan, and 8.93 billion yuan for 2025, 2026, and 2027 respectively, with growth rates of 16%, 17%, and 16% [5]. - The net profit forecast for the same years is 1.31 billion yuan, 1.52 billion yuan, and 1.78 billion yuan, with growth rates of 15%, 16%, and 17% [5]. - The earnings per share (EPS) are expected to be 1.29 yuan, 1.50 yuan, and 1.75 yuan for 2025, 2026, and 2027 respectively [5]. - The company is considered to be relatively undervalued, and the report maintains a "Buy" rating based on its growth potential and diverse product pipeline [5].

Group 1 - The company reported Q1 2025 revenue of 1.51 billion yuan, a year-on-year increase of 11.3%, and a net profit attributable to shareholders of 300 million yuan, up 13.4% year-on-year [1] - In Q1 2025, the company's gross profit margin and net profit margin were 74.7% and 19.9%, respectively, with various expense ratios increasing, including sales expense ratio at 33.6% (up 1.5 percentage points year-on-year) [1] - The increase in management expenses was mainly due to higher stock incentive costs and amortization of franchise fees, while R&D expenses rose due to increased R&D investment and stock incentive costs [1] Group 2 - The company invested 721 million yuan in R&D in 2024, a year-on-year increase of 17.48%, with R&D personnel reaching 911, up 6.7% year-on-year [2] - The company has 14 innovative drug projects in development, with NH600001 completing Phase III clinical trials and expected to submit NDA within the year [2] - Other projects are at various clinical stages, including NHL35700 tablets and NH102 tablets in Phase II, and several others in Phase I or preclinical research [2] Group 3 - The company maintains revenue forecasts of 6.59 billion yuan, 7.69 billion yuan, and 8.93 billion yuan for 2025-2027, with growth rates of 16%, 17%, and 16% respectively [3] - Net profit attributable to shareholders is projected to be 1.31 billion yuan, 1.52 billion yuan, and 1.78 billion yuan for the same period, with growth rates of 15%, 16%, and 17% respectively [3] - The company is considered to be relatively undervalued, and given its growth potential and rich product pipeline, a "buy" rating is maintained [3]

证券代码：002262 证券简称：恩华药业 公告编号：2025-026 江苏恩华药业股份有限公司 2024年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 公司声明：本次实施的分配方案与股东大会审议通过的分配方案及其调整原则一致，距 离股东大会审议通过利润分配方案的时间未超过两个月。 一、股东大会审议通过的利润分配方案等情况 1、2025年4月25日召开的2024年度股东大会审议通过了《2024年度利润分配预案》。公 司2024年度利润分配方案为：以公司2024年12月31日总股本1,016,176,792股为基数，向全体 股东每10股派发现金红利3.60元（含税），本年度现金分红金额预计365,823,645.12元，占 2024年度归属于上市公司股东净利润的31.99%，不送红股，亦不进行资本公积转增股本。本 次利润分配方案实施后留存未分配利润5,264,037,386.86元，结转以后年度进行分配。分配 预案公布后至实施前，如公司总股本由于可转债转股、股份回购、股权激励行权、再融资新 增股份上市等原因发生变动，则以实施分配方案股权登 ...

新华社北京4月28日电 中共中央 国务院关于表彰全国劳动模范和先进工作者的决定 （2025年4月28日） 近年来，在以习近平同志为核心的党中央坚强领导下，全党全国各族人民砥砺奋进、攻坚克难， 中国式现代化迈出新的坚实步伐。在这一伟大实践中，涌现出一大批敬业奉献、锐意进取、忘我 拼搏、敢为人先的先进模范人物。他们是千千万万奋斗在各行各业劳动群众中的杰出代表，以自 身的模范行动和崇高品格，生动诠释了劳模精神、劳动精神、工匠精神的时代内涵，充分展现了 新时代我国工人阶级和广大劳动群众的崭新风采。为表彰他们的突出贡献，进一步凝聚起团结奋 进的强大力量，党中央、国务院决定，授予徐树永等1670人全国劳动模范称号，授予李萌等756人 全国先进工作者称号。 希望获得全国劳动模范和先进工作者称号的同志，珍惜荣誉、保持本色，实干笃行、再立新功， 充分发挥模范带头作用，激励广大劳动群众踊跃投身以高质量发展推进中国式现代化的火热实 践。 党中央号召，全党全国各族人民要以习近平新时代中国特色社会主义思想为指导，深入贯彻落实 党的二十大和二十届二中、三中全会精神，以全国劳动模范和先进工作者为榜样，深刻领悟"两个 确立"的决定性意义，增 ...

Group 1: Company Performance and Sales - The company achieved approximately 1 billion in sales for Antitan after leveraging its sales channel advantages [2] - Oxycodone generated nearly 5 billion in revenue last year, indicating strong market performance [2] - The sales target for Midazolam injection in 2024 is projected to reach around 7 billion [2] - The company expects a sales figure of 2 billion for Oligo in 2025, with over 1,500 hospitals anticipated to adopt the product [1] Group 2: Market Strategy and International Expansion - Domestic sales account for 98.55% of total sales, while international sales represent only 0.41% [1] - The company plans to accelerate international expansion through external product introductions and self-developed project licensing [1] - The company is focusing on strategic partnerships and licensing opportunities to enhance its international presence [4] Group 3: Product Development and Pipeline - NH600001 is progressing well, with NDA submission expected in the second half of this year and approval anticipated in the first half of 2027 [1] - The company is developing long-acting formulations, including Aripiprazole long-acting injection, currently in clinical stages [3] - NH102, NH130, and NH160030 are innovative drug projects in clinical phases, targeting depression and Parkinson's disease symptoms [4] Group 4: Market Challenges and Regulatory Impact - The company acknowledges ongoing challenges in the pain management sector due to competition from other firms [1] - The impact of national procurement policies on the company's operations is considered minimal, but local procurement remains uncertain [2] - The company aims for double-digit growth despite the challenges posed by procurement policies [2] Group 5: Future Outlook and Growth Projections - The company anticipates double-digit growth in the anesthesia, mental health, and neurological sectors [6] - Strategic focus on core competencies is expected to enhance competitive advantages in the market [7] - The company is optimistic about achieving a robust growth trajectory over the next 3-5 years [4]

证券代码：002262 证券简称：恩华药业 公告编号：2025-025 江苏恩华药业股份有限公司 2024年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 特别提示： 1、本次股东大会无否决提案的情况。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 3、为了尊重中小投资者权益（中小投资者是指以下股东以外的其他股东：①上市公司的 董事、监事、高管；②单独或者合计持有上市公司5%以上股份的股东），提高中小投资者对 股东大会重大决议事项的参与度，本次股东大会对中小投资者表决单独计票。 一、会议召开情况 （一）召开时间 现场会议召开时间：2025年4月25日（星期五）上午9：00。 网络投票时间：通过深圳证券交易所（以下简称"深交所"）交易系统进行网络投票的具体 时间为2025年4月25日的交易时间，即9:15—9:25，9:30—11:30和13:00—15:00；通过深交所互 联网投票系统投票的具体时间为2025年4月25日9:15至15:00的任意时间。 （二）现场会议召开地点：徐州市经济技术开发区龙湖西路31号恩华科技大厦3楼301 ...

北京市立方律师事务所 北京市立方律师事务所 关于江苏恩华药业股份有限公司 2024 年度股东大会的 法律意见书 2025 年 4 月 关于江苏恩华药业股份有限公司 2024 年度股东大会的 法律意见书 致：江苏恩华药业股份有限公司 根据《中华人民共和国证券法》 、《中华人民共和国公司法》(以下简称"《公司 法》")、《上市公司股东大会规则》(以下简称"《股东大会规则》")、《律师事务 所从事证券法律业务管理办法》(以下简称"《证券法律业务管理办法》") 等 相关法律、法规和规范性文件以及《江苏恩华药业股份有限公司公司章程》(以 下简称"《公司章程》") 的规定，北京市立方律师事务所 (以下简称"本所") 指 派律师出席江苏恩华药业股份有限公司 (以下简称"恩华药业")2024 年度股东 大会 (以下简称"本次股东大会")， 并出具本法律意见书。 对本法律意见书的出具，本所律师特作如下声明： 1、本所律师已经按照《股东大会规则》的要求对本次股东大会的真实性、 合 法性进行了核查和验证 (以下简称"查验") 并发表法律意见，本法律意见书中 不存在虚假记载、误导性陈述及重大遗漏。 2、本所律师仅对恩华药业本次股东大 ...

Investment Rating - The investment rating for Jiangsu Nhwa Pharmaceutical Co. is Neutral, with a 12-month price target of Rmb28, indicating an upside potential of 25.2% from the current price of Rmb22.37 [6][2]. Core Insights - Jiangsu Nhwa Pharmaceutical Co. is a leading manufacturer of psychiatric drugs and anesthetics in China, with growth drivers including the ramp-up of its licensed-in asset TRV-130 and newly approved generic drugs [2]. - The company's 1Q25 results showed revenue of Rmb1,511 million, representing an 11% year-over-year increase, and a net profit of Rmb301 million, up 13% year-over-year, which were in line with expectations [1]. - The report indicates that only 0.4% of the company's total revenue in 2024 was from overseas markets, with minimal exposure to the US market, suggesting limited tariff impact [1]. Financial Projections - Revenue projections for Jiangsu Nhwa Pharmaceutical Co. are as follows: Rmb5,697.6 million for 2024, Rmb6,531.9 million for 2025, Rmb7,513.2 million for 2026, and Rmb8,698.0 million for 2027 [6]. - EBITDA estimates are projected to be Rmb1,376.4 million for 2024, Rmb1,583.4 million for 2025, Rmb1,862.9 million for 2026, and Rmb2,206.4 million for 2027 [6]. - Earnings per share (EPS) estimates are Rmb1.13 for 2024, Rmb1.29 for 2025, Rmb1.50 for 2026, and Rmb1.77 for 2027 [6]. Key Catalysts - Important events to monitor include the ramp-up pace of TRV-130 and the potential for volume-based procurement (VBP) in anesthetics, which could impact the company's growth trajectory [2].

Group 1 - The core viewpoint of the news is the performance and holdings of the Huatai Fuhua Medical Active Growth One-Year Holding Mixed Fund A, which has shown positive growth in its net value and returns over various time frames [1]. - The latest net value of the fund is 0.5868 yuan, reflecting a growth of 1.58% [1]. - The fund's performance over the past month has yielded a return of 7.20%, ranking 51 out of 4672 in its category [1]. - Over the past three months, the fund has achieved a return of 18.62%, ranking 96 out of 4599 [1]. - Year-to-date, the fund has returned 18.31%, ranking 123 out of 4590 [1]. Group 2 - The top ten stock holdings of the fund account for a total of 47.35%, with significant positions in companies such as Kangfang Biotech (7.08%), Keren Biotechnology (7.04%), and Betta Pharmaceuticals (5.10%) [1]. - The fund was established on August 21, 2020, and as of December 31, 2024, it has a total scale of 1.501 billion yuan [1]. - The fund manager is Zheng Lei, who has extensive experience in the investment management field, having previously worked with various financial institutions [2].

Financial Performance - The company reported a total revenue of 1.511 billion yuan for Q1 2025, an increase of 11.29% year-on-year [1] - The net profit attributable to shareholders reached 301 million yuan, reflecting a year-on-year growth of 13.35% [1] - The gross profit margin improved to 74.69%, up by 5.53% compared to the previous year [1] - The net profit margin also increased to 19.9%, a rise of 2.08% year-on-year [1] - The company's operating cash flow per share was 0.31 yuan, marking a significant increase of 35.53% year-on-year [1] Accounts Receivable and Liabilities - Accounts receivable rose significantly, with a year-on-year increase of 50.86%, reaching 1.686 billion yuan [1] - The company reduced its interest-bearing liabilities by 62.21%, bringing them down to 31.721 million yuan [1] Market Position and Analyst Insights - The company's return on invested capital (ROIC) was reported at 16.19%, indicating strong capital returns [3] - Analysts expect the company's revenue for 2025 to be around 1.32 billion yuan, with an average earnings per share forecast of 1.3 yuan [3] - The company has a notable presence among institutional investors, with a prominent fund manager recently increasing their stake [3] Fund Holdings - The largest fund holding the company’s shares is the Huatai-PineBridge Innovation Medicine Mixed Fund, which has a scale of 4.675 billion yuan [4] - The fund manager of this fund has a strong track record, ranking second in the 2024 public fund manager list [4] Strategic Plans - The company plans to accelerate the launch of new drugs and enhance the promotion of existing non-collection products while managing costs effectively [5]